A common single nucleotide polymorphism impairs B-cell activating factor receptor's multimerization, contributing to common variable immunodeficiency - 29/03/14

| This work was supported by the German Cancer Research Fund (grant no. 108935 to H.E. and K.P.), the European Union 7th framework grant (no. HEALTH-F2-2008-201549 to H.E., B.G., U.S., L.H., V.L., and A.P.), the Federal Ministry of Education and Research (grant no. BMBF 01 E0 08 03 to M. Rizzi), the Swiss National Science Foundation (grant no. PASMP3-127678/1 to M. Recher and grant no. 31003A_138065 to P.S.), Merck-Serono (to P.S.), and the Deutsche-Forschungsgemeinschaft (grant no. TRR130 TP06 to H.E., grant no. EXC294 to W.W.S., and SFB620 project C7 to U.S.). |
|
| Disclosure of potential conflict of interest: M. Speletas is employed by the University of Thessaly; has received research support from General Secretariat of Research; has received lecture fees from Amgen Hellas for immunology lectures; and has received travel fees from Shire Hellas, Behring Hellas, and Bristol-Meyer Hellas. L. Hammarstrom has received research support from the Swedish Research Council. M. Recher has received research support from the Swiss National Science Foundation and the University of Basel, Switzerland. A. E. Germenis has received consultant fees from Novartis and Shire, is employed by the University of Thessaly, has received lecture fees from Amgen and Novartis, and has received travel fees from Shire. B. Grimbacher has received research support from University College London (UCL) (FP7 Eu Grant [EURO-PADnet Health-F2-2008-201549]) and Uniklinik Freiburg (BMBF 01 Eo0803); is employed by UCL; receives royalties from Springer; and has received travel fees from CSL Behring, the American Academy of Allergy, Asthma & Immunology, Japanese Society of Immunodeficiency, European Society of Immunodeficiency, Latin American Society of Immunodeficiency, Primary Immunodeficiency Meeting. K. Warnatz has received research support and travel support from EURPADnet EU-FP7; has received lecture fees and honoraria from Baxter, GlaxoSmithKline, CSL Behring, Pfizer, the American Academy of Allergy, Asthma & Immunology, Biotest, and Novartis Pharma; is employed by a CCI grant from Bundesministerium für Bildung und Forschung; has research support pending from Deutsche Forschungsgesellschaft; and has received fees for manuscript preparation from UCB Pharma. P. Schneider has received research support from Merck-Serono and Edimer Pharmaceuticals and receives royalties from Adipogen. L. D. Notarangelo is a board member for a program in Molecular and Cellular Medicine, the Pediatric University Hospital “meyer,” and the Board of Scientific Counselors, the National Institues of Allergy and Infectious Diseases, and the National Institutes of Health (NIH); is employed by Boston Children's Hospital; has received research support from the NIH and March of Dimes; and receives royalties from UpToDate. H. Eibel has received research support from the German Cancer Research Fund and Deutsche Forschungsgemeinschaft. The rest of the authors declare that they have no relevant conflicts of interest. |
Vol 133 - N° 4
P. 1222 - avril 2014 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
